All In Biotech

Free tool

FAERS Monitor: Ozempic

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209637 or its brand name (Ozempic, Semaglutide). Reports on generic versions are filed under their own applications.

Reports

70,721

Serious

35,100

50% of reports

Hospitalization

13,974

Death reported

1,193

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea10,175
  • off label use7,482
  • vomiting6,675
  • diarrhoea6,326
  • decreased appetite4,685
  • constipation4,636
  • weight decreased4,425
  • impaired gastric emptying4,024
  • product use in unapproved indication3,555
  • blood glucose increased3,101
  • wrong technique in product usage process3,008
  • abdominal pain upper2,957
  • fatigue2,956
  • headache2,926
  • weight increased2,695

Reports by year received

View as table
YearReports
20132
20143
20157
201612
201713
20181,140
20191,589
20203,032
20213,730
20225,301
20238,478
202412,875
202518,612
202615,927

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,983,438 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
impaired gastric emptyingSignal4,024124.1119.7346,564
constipationSignal4,6366.46.321,054
decreased appetiteSignal4,6856.15.919,795
blood glucose increasedSignal3,1015.04.89,726
weight decreasedSignal4,4254.84.613,163
wrong technique in product usage processSignal3,0084.54.38,046
abdominal pain upperSignal2,9574.34.27,504
product use in unapproved indicationSignal3,5554.34.29,022
vomitingSignal6,6754.34.216,843
nauseaSignal10,1753.93.822,116
weight increasedSignal2,6953.63.55,077
diarrhoeaSignal6,3262.92.98,234
off label useSignal7,4822.62.57,321
headache2,9261.41.3328
fatigue2,9561.11.145

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.